NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $4 | $55 | $78 | $87 |
| % Growth | -92% | -29% | -10.9% | – |
| Cost of Goods Sold | $2 | $6 | $8 | $164 |
| Gross Profit | $2 | $49 | $70 | -$77 |
| % Margin | 49.7% | 89.2% | 89.9% | -87.7% |
| R&D Expenses | $112 | $181 | $162 | $164 |
| G&A Expenses | $38 | $41 | $37 | $27 |
| SG&A Expenses | $37 | $41 | $37 | $27 |
| Sales & Mktg Exp. | -$1 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$1 |
| Operating Expenses | $149 | $222 | $199 | $191 |
| Operating Income | -$147 | -$166 | -$121 | -$104 |
| % Margin | -3,317.8% | -300.5% | -155% | -118.8% |
| Other Income/Exp. Net | $4 | $4 | $0 | $1 |
| Pre-Tax Income | -$142 | -$163 | -$120 | -$102 |
| Tax Expense | $0 | -$4 | -$7 | -$8 |
| Net Income | -$142 | -$159 | -$114 | -$94 |
| % Margin | -3,223.3% | -287.5% | -146.2% | -107.6% |
| EPS | -1.73 | -1.99 | -1.48 | -1.37 |
| % Growth | 13.1% | -34.5% | -8% | – |
| EPS Diluted | -1.73 | -1.99 | -1.48 | -1.37 |
| Weighted Avg Shares Out | 82 | 80 | 77 | 68 |
| Weighted Avg Shares Out Dil | 82 | 80 | 77 | 68 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $4 | $0 | $2 |
| Interest Expense | $0 | $4 | $0 | $0 |
| Depreciation & Amortization | $2 | $4 | $6 | $7 |
| EBITDA | -$144 | -$155 | -$121 | -$104 |
| % Margin | -3,267.5% | -280% | -155% | -118.8% |